Hikma Pharmaceuticals (LON:HIK) Stock Price Down 14.1% – What’s Next?

Hikma Pharmaceuticals PLC (LON:HIK)’s stock price was down 14.1% on Thursday . The company traded as low as GBX 1,522 and last traded at GBX 1,522. Approximately 166,325,172 shares were traded during trading, an increase of 7,989% from the average daily volume of 2,056,107 shares. The stock had previously closed at GBX 1,771.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on HIK shares. JPMorgan Chase & Co. cut their target price on shares of Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500 and set an “overweight” rating for the company in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating for the company in a research report on Tuesday, August 12th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,600 price objective on shares of Hikma Pharmaceuticals in a research note on Thursday, August 7th. Finally, Berenberg Bank reduced their price objective on shares of Hikma Pharmaceuticals from GBX 2,560 to GBX 2,510 and set a “buy” rating for the company in a research note on Thursday, October 16th. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of GBX 2,615.

Hikma Pharmaceuticals Trading Down 14.1%

The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66. The stock’s 50-day simple moving average is GBX 1,734.94 and its 200-day simple moving average is GBX 1,896.07. The firm has a market capitalization of £3.37 billion, a PE ratio of 9.11, a P/E/G ratio of 2.38 and a beta of 0.41.

Insiders Place Their Bets

In related news, insider Mazen Darwazah acquired 14,000 shares of Hikma Pharmaceuticals stock in a transaction on Tuesday, September 16th. The shares were acquired at an average cost of GBX 1,603 per share, with a total value of £224,420. Also, insider Laura Balan Balan acquired 3,500 shares of Hikma Pharmaceuticals stock in a transaction on Friday, August 22nd. The shares were bought at an average cost of GBX 1,821 per share, for a total transaction of £63,735. 17.77% of the stock is currently owned by insiders.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.